MEDAG enhances breast cancer progression and reduces epirubicin sensitivity through the AKT/AMPK/mTOR pathway

Zhiyu Li(Wuhan University), Shengrong Sun(Wuhan University)
Cell Death and Disease
January 18, 2021
Cited by 32


Related Papers